Changeflow GovPing Government & Legislation DNA Research on Station Promoting Cancer Therap...
Routine Notice Added Final

DNA Research on Station Promoting Cancer Therapies, Radiation Repair

Favicon for www.nasa.gov NASA Press
Published
Detected
Email

Summary

NASA astronauts Chris Williams and Sophie Adenot processed DNA Nano Therapeutics-3 experiment samples in the Kibo laboratory module aboard the International Space Station on April 22, 2026, exploring DNA-inspired assembly techniques for manufacturing nano-therapies such as chemotherapy and immunotherapy to kill cancer cells and activate the immune system. The Expedition 74 crew also tested new exercise hardware, virtual reality goggles for vision screening, and continued unpacking cargo from Northrop Grumman's Cygnus XL resupply ship. Samples will be analyzed on the orbital outpost with a spectrophotometer then returned to Earth for further analysis.

“The investigation is exploring DNA-inspired assembly techniques as a way to manufacture treatments, or nano-therapies such as chemotherapy and immunotherapy, to kill cancer cells and activate the immune system.”

NASA , verbatim from source
Published by NASA on nasa.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors NASA Press for new government & legislation regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

NASA published a blog update describing ongoing biotechnology research aboard the International Space Station involving DNA Nano Therapeutics-3, which explores DNA-inspired assembly techniques for manufacturing cancer treatments including chemotherapy and immunotherapy nano-therapies. The research leverages the microgravity environment to study how bacteria affect heart tissue and how DNA damaged by space radiation repairs itself.

The research activities described are informational scientific updates with no compliance obligations or regulatory implications for external parties. Companies in the biotechnology and pharmaceutical sectors may find the microgravity-based research relevant to their drug development pipelines, though this document does not create any regulatory requirements or reporting obligations.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Mark A. Garcia

April 22, 2026 12:24PM

Categories

-

DNA Research on Station Promoting Cancer Therapies, Radiation Repair

NASA astronaut Chris Williams configures research hardware inside a portable glovebag for a biotechnology investigation exploring how bacteria affect heart tissue in the microgravity environment. NASA/Jessica Meir

More biotechnology research was underway aboard the International Space Station on Wednesday taking advantage of the microgravity environment to boost knowledge about the properties of DNA and DNA-like nanomaterials. The Expedition 74 crew also completed the installation of an advanced exercise device and tested a set of new virtual reality goggles while continuing to unpack a U.S. cargo spacecraft.

Flight engineers Chris Williams of NASA and Sophie Adenot of ESA (European Space Agency) joined each other in the Kibo laboratory module processing samples of genetic materials for the DNA Nano Therapeutics-3 experiment. The investigation is exploring DNA-inspired assembly techniques as a way to manufacture treatments, or nano-therapies such as chemotherapy and immunotherapy, to kill cancer cells and activate the immune system. The manufactured samples will be analyzed first on the orbital outpost with a spectrophotometer then returned to Earth for more analysis.

NASA flight engineer Jessica Meir began her shift swapping scientific hardware inside the Columbus laboratory module ’s BioLab, an incubator supporting research into the effects of microgravity on small organisms. The science maintenance work is supporting the Lux in Space investigation that observes how DNA damaged by space radiation repairs itself. While still working inside Columbus, Meir checked and secured power connections for the new European Enhanced Exploration Exercise Device, or E4D. The E4D is being tested for its ability to support crew workouts on missions to the Moon, Mars, and beyond. Finally, Meir reviewed the Nevada Vision Screening System, a head-mounted virtual reality display that measures as astronaut’s visual function to protect eyesight in space.

NASA flight engineer Jack Hathaway worked throughout Wednesday supporting his crewmates with the scientific work then continued with cargo transfers and medical inventory management. He first activated Kibo’s Life Science Glovebox enabling Williams and Adenot to work on the DNA therapy study then photographed Meir as she swapped hardware on the BioLab. Next, Hathway unpacked more cargo from Northrop Grumman’s Cygnus XL resupply ship then refilled the Columbus lab’s Human Research Facility with medical gear including blood tube kits, needles, electrodes, and gloves.

Working together in the Roscosmos segment of the orbital outpost, flight engineers Sergei Mikaev and Andrey Fedyaev participated in a fitness evaluation. Mikaev pedaled on an exercise cycle while attached to sensors measuring his cardiac activity while Fedyaev assisted him. Next, Fedyaev tested the operation of the Zvezda service module ’s treadmill then worked on the Nauka science module ’s orbital plumbing system.

Later, Mikaev joined station commander Sergey Kud-Sverchkov and began configuring simulation hardware that will help the duo prepare for the automated rendezvous and docking of the Progress 95 cargo mission planned for 8 p.m. EDT on Monday, April 27. Kud-Sverchkov also worked inside the Zarya module replacing battery units inside its power supply system.

Learn more about station activities by following the space station blog , @space_station on X, as well as the ISS Facebook and ISS Instagram accounts.

Get the latest from NASA delivered every week. Subscribe here .

Mark A. Garcia

April 22, 2026 12:24PM

Categories

-

-

Get daily alerts for NASA Press

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NASA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NASA
Published
April 22nd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Pharmaceutical companies Researchers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Scientific research Biotechnology investigation Drug development
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Biotechnology Pharmaceuticals Scientific Research

Get alerts for this source

We'll email you when NASA Press publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!